RegCell venture announces study on iPS treatment for rheumatoid arthritis

RegCell Co. is a spin-out of Osaka University’s Immunological Frontier Research Center (IFReC), supported by iPS portal, Kyoto City. The company will attempt to apply autologous regulatory T cells for the treatment of rheumatoid arthritis.

https://regcell.jp

Most popular posts: